

Food and Drug Administration College Park, MD 20740

1733 5 JUN 22 P2:18

JUN 1 4 2005

Mr. Robert S. Rister Consultant to Organix South, Inc. 6290-B 147<sup>th</sup> Avenue North Clearwater, Florida 33760

Dear Mr. Rister:

This is in response to your letter of April 22, 2005 to the Food and Drug Administration (FDA) pursuant to 21 U.S.C. 343(r)(6) (section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the Act)). Your letter states that the following statements, among others, will be made for the product Narsimha: "Heart Cholesterol Support" and "[S]upport healthy LDL...levels...."

In the preamble to the January 6, 2000 final rule on structure/function claims (see 65 FR 1000 at 1018), FDA stated that claims about the maintenance of normal cholesterol levels did not necessarily constitute implied disease claims. We stated, however, that because "many people think of cholesterol solely in terms of the negative role of elevated cholesterol in heart disease," in order to avoid implying that the product prevents or treats heart disease, a cholesterol maintenance claim would have to clarify that the product is only for maintenance of cholesterol levels that are already within the normal range. Therefore, because the claims you are making for this product represent that the product is intended to affect blood cholesterol but do not also include statements about it being intended to affect blood cholesterol that is already in the normal range, they are implied disease claims.

Your product label also contains the statements "[H]elping the arteries remain flexible" and "[K]eeps the white blood cells known as granulocytes from upsetting balance in the lining of the arteries." In light of the claims made about cholesterol and heart health, these claims are implied disease claims in that they imply the product will also prevent coronary heart disease.

21 U.S.C. 343(r)(6) makes clear that a statement included in labeling under the authority of that section may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases. The statements that you are making for this product suggest that it is intended to treat, prevent, or mitigate a disease. These claims do not meet the requirements of 21 U.S.C. 343(r)(6). These claims suggest that this product is intended

## Page 2 - Mr. Robert S. Rister

for use as a drug within the meaning of 21 U.S.C. 321(g)(1)(B), and that it is subject to regulation under the drug provisions of the Act. If you intend to make claims of this nature, you should contact FDA's Center for Drug Evaluation and Research (CDER), Office of Compliance, HFD-310, Montrose Metro II, 11919 Rockville Pike, Rockville, Maryland 20855.

Please contact us if we may be of further assistance.

Sincerely yours,

Susan J. Walker, M.D.

Director

Division of Dietary Supplement Programs Office of Nutritional Products, Labeling

and Dietary Supplements

Center for Food Safety and Applied Nutrition

Copies:

FDA, Center for Drug Evaluation and Research, Office of Compliance, HFD-310 FDA, Office of the Associate Commissioner for Regulatory Affairs, Office of Enforcement, HFC-200

FDA, Florida District Office, Office of Compliance, HFR-SE240

Organix-South, Inc. 6290-B 147th Avenue North Clearwater, FL 33760

> Phone: 727-531-8801 Fax: 727-531-8807

Email: Rob@organixsouth.com

April 22, 2005

Office of Special Nutritionals (HFS-450)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 C St. SW
Washington, DC 20204

## NOTICE OF DESCRIPTIVE CLAIMS

Enclosed herewith are texts of descriptive claims made by Organix South on or after April 22, 2005:

AJAY
ANITA
KAMA
MANISH
NARSIMHA
NARTANA
NEEM
NIRMAL
NISHA
PAVAN
SAHANA
THERA NEEM
THERA NEEM LEAF
USHA

Text of statement, name of supplement, identification of manufacturer, and contact information for each product are included on its sheet. I certify that these exhibits are accurate copies of the originals and that the firm has acquired substation that statements therein are truthful and not misleading.

Sincerely,

**VIJAY** 

Robert S. Rister

Consultant to Organix South, Inc.

6. RIGIES

#1203

Supercritical Whole Herb Technology TheraVeda supplements provide the benefits of chemical-free herbal extracts and natural whole herbs through an innovative, patent-pending technology that uses no harmful chemical solvents. Supercritical extraction is a natural process that makes powerful herbal extracts containing the broadest spectrum of an herb's essential nutrients. Our unique technology concentrates the supercritical extract with the post-supercritical extract. This is then combined with the whole herb in a vegetarian capsule achieving the broad spectrum previously only available with whole herb supplements, but now in a concentrated extract formula.\*

TheraVeda's Narsimba formula was developed using unique herbs to support the heart by meintaining lipid metabolism and promoting healthy cholesterol levels.\*

Organic South's Thera Voda." vegetarian capsules contain NO corn, soy, salt, yeast, sugar, wheat, egg or dany products and are formulated without the use of preservatives, artificial flavors or colors. Our premium vegetarian capsules are prepared without any chemical solvents and are independently verified to be free of pesticides and harmful levels of heavy metal contaminants.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to disgnose, treat, care or prevent any

*Higg* Veda Fermulated & distributed by:


Organix-South, Inc., Clearwater, M. 33750

60

SUPERCRITICAL VEGETARIAN

CAPSULES

www.theravedaberbs.com x-885-959-6336 SUPERCRITICAL TECHNOLOGY INSPIRED BY AYURVEDIC WISDOM



Narsinia

Heart Cholesterol Support \*

DIFTARY SUPPLEMENT

PATENT PENDING
WHOLE HERB TECHNOLOGY

Wheresoever your heart.' - Chinese - Chinese



Narsimha, in the Indian language, means the Lion Among Men, or LIONHEARTED.

Commiphera mukul, also known as guggal or guggulu, is a resin collected from the bark of the myrrh tree. The "guggulipid" extracted from the herb is widely reported to support healthy LDL and HDL levels, helping the arteries remain flexible. Turmeric is a source of the antiexidant curcumin. Exactly how curcumin affects circulation is not entirely understood, but scientists theorize that it keeps the white blood cells known as granulocytes from upsetting balance in the lining of the arteries. Timospora is a bitter, stimulating good digestion—thorough digestion of food shortens the time bloodstream concentrations of fats are elevated after a meal of fatty foods. Defatted fenugreek supports proper fluid levels without depleting minerals, and provides hencicial tibers—helping to prevent fat accumulation."

Avurveda teaches that any heart can benefit from a calm, orderly, planned lifestyle. Avoiding heavy meals, getting a good night's sleep, and patiently dealing with stress will make any heart work better.

## **Supplement Facts**

Serving size: 2 capsules Serving per container: 30

Amount Per Serving % Daily Value

Commiphora mukul SCO2 extract (1:100) 10 mg •

Commiphora mukul PSE\*\*
hydrophilic extract (min 2.5%
gugguisterones E&Z 2.5 mg)

90 mg •

Turmeric (rhizome) SCO2 100 mg extract (55% turmerone 55 mg & 11% curcuminoids 11 mg)

Tinospora cardifolia (stem) SCO2 extract (70:1)20 mg

Tinospora cardifolia (stern) 150 mg • PSE\*\* hydrophilic extract (2% bitters 3 mg)

Defatted Fenugreek (seed) powder 460 mg •

Daily Value not established

en gelterbischen biet einen oppeter (an

Additives. No animal incredient

Same of the Laydrophilic Estuact

Butter (Billy Little 1 gapsule

able alletany of perbal south Arease your learns for using the prodict of pregners or considering consumers the product.